H.C. Wainwright analyst Ed Arce downgraded CymaBay Therapeutics (CBAY) to Neutral from Buy with a price target of $32.50, up from $28, citing the pending takeover by Gilead (GILD). The takeout consideration “is more than adequate, if not generous, in our view, and likely reflects to some degree the operational and commercial synergies that perhaps only Gilead could bring to bear,” the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- M & A News: Gilead (NASDAQ:GILD) to Acquire CymaBay
- CymaBay Therapeutics’ Strategic Merger with Gilead Sciences
- CymaBay Therapeutics to Participate in Upcoming Investment Conferences
- CymaBay price target raised to $26 from $22 at Oppenheimer
- CymaBay Therapeutics Boosts Director Equity, Announces Officer Changes